These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26849104)

  • 21. In vitro and in vivo evaluation of riccardin D nanosuspensions with different particle size.
    Liu G; Zhang D; Jiao Y; Guo H; Zheng D; Jia L; Duan C; Liu Y; Tian X; Shen J; Li C; Zhang Q; Lou H
    Colloids Surf B Biointerfaces; 2013 Feb; 102():620-6. PubMed ID: 23107940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Downstream drug product processing of itraconazole nanosuspension: Factors influencing drug particle size and dissolution from nanosuspension-layered beads.
    Parmentier J; Tan EH; Low A; Möschwitzer JP
    Int J Pharm; 2017 May; 524(1-2):443-453. PubMed ID: 28400290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nanosizing of valsartan by high pressure homogenization to produce dissolution enhanced nanosuspension: pharmacokinetics and pharmacodyanamic study.
    Gora S; Mustafa G; Sahni JK; Ali J; Baboota S
    Drug Deliv; 2016; 23(3):940-50. PubMed ID: 24937379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design of self-dispersible dry nanosuspension through wet milling and spray freeze-drying for poorly water-soluble drugs.
    Niwa T; Danjo K
    Eur J Pharm Sci; 2013 Nov; 50(3-4):272-81. PubMed ID: 23907001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gelucire and Gelucire-PEG400 formulations; tolerability in species used for non-clinical safety testing after oral (gavage) dosing.
    Elander M; Boll JB; Hojman AS; Rasmussen AD
    J Appl Toxicol; 2016 Nov; 36(11):1430-6. PubMed ID: 26849184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanosizing of poorly water soluble compounds using rotation/revolution mixer.
    Takatsuka T; Endo T; Jianguo Y; Yuminoki K; Hashimoto N
    Chem Pharm Bull (Tokyo); 2009 Oct; 57(10):1061-7. PubMed ID: 19801859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double controlled release of highly insoluble cilostazol using surfactant-driven pH dependent and pH-independent polymeric blends and in vivo bioavailability in beagle dogs.
    Nam KY; Cho SM; Choi YW; Park C; Meghani NM; Park JB; Lee BJ
    Int J Pharm; 2019 Mar; 558():284-290. PubMed ID: 30641181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development and in vitro evaluation of deacety mycoepoxydiene nanosuspension.
    Wang Y; Liu Z; Zhang D; Gao X; Zhang X; Duan C; Jia L; Feng F; Huang Y; Shen Y; Zhang Q
    Colloids Surf B Biointerfaces; 2011 Apr; 83(2):189-97. PubMed ID: 21176876
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lutein nanocrystals as antioxidant formulation for oral and dermal delivery.
    Mitri K; Shegokar R; Gohla S; Anselmi C; Müller RH
    Int J Pharm; 2011 Nov; 420(1):141-6. PubMed ID: 21884768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Process parameter dependent growth phenomena of naproxen nanosuspension manufactured by wet media milling.
    Bitterlich A; Laabs C; Krautstrunk I; Dengler M; Juhnke M; Grandeury A; Bunjes H; Kwade A
    Eur J Pharm Biopharm; 2015 May; 92():171-9. PubMed ID: 25766272
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new and improved method for the preparation of drug nanosuspension formulations using acoustic mixing technology.
    Leung DH; Lamberto DJ; Liu L; Kwong E; Nelson T; Rhodes T; Bak A
    Int J Pharm; 2014 Oct; 473(1-2):10-9. PubMed ID: 24984068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of stabilizing agents on the development of myricetin nanosuspension and its characterization: an in vitro and in vivo evaluation.
    Hong C; Dang Y; Lin G; Yao Y; Li G; Ji G; Shen H; Xie Y
    Int J Pharm; 2014 Dec; 477(1-2):251-60. PubMed ID: 25445518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Methods to evaluate and improve the injection site tolerability of intravenous formulations prior to first-in-human testing.
    Eichenbaum G; Zhou J; De Smedt A; De Jonghe S; Looszova A; Arien T; Van Goethem F; Vervoort I; Shukla U; Lammens L
    J Pharmacol Toxicol Methods; 2013; 68(3):394-406. PubMed ID: 23933112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced bioavailability of cinnarizine nanosuspensions by particle size engineering: Optimization and physicochemical investigations.
    Mishra B; Sahoo J; Dixit PK
    Mater Sci Eng C Mater Biol Appl; 2016 Jun; 63():62-9. PubMed ID: 27040196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. USP Apparatus 4: a Valuable In Vitro Tool to Enable Formulation Development of Long-Acting Parenteral (LAP) Nanosuspension Formulations of Poorly Water-Soluble Compounds.
    Forrest WP; Reuter KG; Shah V; Kazakevich I; Heslinga M; Dudhat S; Patel S; Neri C; Mao Y
    AAPS PharmSciTech; 2018 Jan; 19(1):413-424. PubMed ID: 28755052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol.
    Jinno J; Kamada N; Miyake M; Yamada K; Mukai T; Odomi M; Toguchi H; Liversidge GG; Higaki K; Kimura T
    J Control Release; 2008 Aug; 130(1):29-37. PubMed ID: 18582979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fabrication of multicomponent amorphous bufadienolides nanosuspension with wet milling improves dissolution and stability.
    Zuo W; Qu W; Li N; Yu R; Hou Y; Liu Y; Gou G; Yang J
    Artif Cells Nanomed Biotechnol; 2018 Nov; 46(7):1513-1522. PubMed ID: 28906144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimization of formulation and process parameters for the production of nanosuspension by wet media milling technique: effect of Vitamin E TPGS and nanocrystal particle size on oral absorption.
    Ghosh I; Schenck D; Bose S; Ruegger C
    Eur J Pharm Sci; 2012 Nov; 47(4):718-28. PubMed ID: 22940548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rational Design and Characterization of a Nanosuspension for Intraoral Administration Considering Physiological Conditions.
    Baumgartner R; Teubl BJ; Tetyczka C; Roblegg E
    J Pharm Sci; 2016 Jan; 105(1):257-67. PubMed ID: 26852857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A mini review of nanosuspensions development.
    Liu Y; Xie P; Zhang D; Zhang Q
    J Drug Target; 2012 Apr; 20(3):209-23. PubMed ID: 22192053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.